Please login to the form below

Not currently logged in
Email:
Password:

Alacrita appoints Stuart Hendry as associate partner

Joins from medical device firm Sphere Medical

edit-StuartHendryLife sciences management consultancy firm Alacrita has appointed Stuart Hendry as an associate partner.

He will be based in the Cambridge, UK, office and will help serve Alacrita's growing roster of clients in the medical device and diagnostics sectors.

Hendry said: “I am very pleased to join the excellent team at Alacrita and I look forward to contributing to the firm's medtech activities in this extremely exciting time for life sciences and medical devices globally.”

Hendry has over 25 years of experience in the industry and joins the company from Sphere Medical, a UK medical device company, where he worked as CEO.

Prior to Sphere Medical, he held a number of senior operational roles, including at Pfizer Hospital Products, Diametrics and PowderJect and he has also worked as head of life sciences at Scientific Generics.

Mark Wickham, Alacrita partner and head of their medtech practice, added: “We believe that seasoned industry expertise is essential to deliver value to a sophisticated life science client.

“With the addition of Stuart to the partnership, we are better positioned than ever to serve our innovative medtech client who are focussed on bringing complex, differentiated medical solutions to the world's patient populations.”

30th September 2014

From: Marketing

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
90TEN

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics